IL-12 reduces the severity of Sendai virus-induced bronchiolar inflammation and remodeling

• Published in: Cytokine (Philadelphia, Pa.) Pa.), 2003-11, Vol.24 (3), p.103-113
• Main Authors: Stone, Amy E.S., Giguere, Steeve, Castleman, William L.
• Format: Article
• Language: English
• Subjects: Animals; Bronchiolitis - drug therapy; Bronchiolitis - pathology; Bronchiolitis - virology; Fibrosis; IL-12; Inflammation; Interferon-gamma - drug effects; Interferon-gamma - genetics; Interleukin-12 - genetics; Interleukin-12 - metabolism; Interleukin-12 - pharmacology; Lung; Lung - metabolism; Lung - virology; Male; Rats; Rats, Inbred BN; Rats, Inbred F344; Respirovirus Infections - drug therapy; Respirovirus Infections - pathology; Respirovirus Infections - virology; Sendai virus - pathogenicity; Virus
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2003.07.005

The goal of this research was to determine whether differential pulmonary IL-12 gene expression controls susceptibility to Sendai virus-induced chronic airway inflammation and fibrosis in inbred rat strains. Sendai virus-resistant F344 rats and susceptible BN rats were studied from 1 to 14 days following virus inoculation. F344 rats had 3.4-fold higher IL-12 mRNA levels detected by real-time PCR in lung than BN rats as early as two days following inoculation. This increase in mRNA was associated at two days with increased total IL-12 protein and with a 2-fold increase in numbers of bronchiolar, OX-6-positive dendritic cells and an increased number of IL-12 p40-positive, bronchiolar macrophages and dendritic cells ( p